Literature DB >> 18991640

Aminopeptidase N (APN/CD13) as a target for anti-cancer agent design.

Xiaopan Zhang1, Wenfang Xu.   

Abstract

APN is an important zinc dependent metallo-exopeptidase; it has been considered as a suitable target for anti-cancer drug design. In this review we focus on the most effective and the most promising inhibitors of aminopeptidase N. Their binding modes to the enzyme, the attempt to explain the origin of the inhibitory activity, as well as the structure-activity relationship for some of these compounds are discussed. Besides, the structural and electronic requirements of the enzyme active site and the binding pockets, together with the specificity towards the ligands are presented.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991640     DOI: 10.2174/092986708786242840

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  14 in total

1.  Upregulation of soluble resistance-related calcium-binding protein (sorcin) in gastric cancer.

Authors:  Langmei Deng; Tao Su; Aimin Leng; Xiaomei Zhang; Meihua Xu; Lu Yan; Huan Gu; Guiying Zhang
Journal:  Med Oncol       Date:  2009-11-03       Impact factor: 3.064

2.  LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin.

Authors:  Jian-Jun Gao; Zu-Hua Gao; Cui-Rong Zhao; Yi Yuan; Shu-Xiang Cui; Xiao-Fan Zhang; Yan-Na Cheng; Wen-Fang Xu; Wei Tang; Xian-Jun Qu
Journal:  Invest New Drugs       Date:  2010-01-29       Impact factor: 3.850

Review 3.  Adeno-associated virus (AAV) vectors in cancer gene therapy.

Authors:  Jorge L Santiago-Ortiz; David V Schaffer
Journal:  J Control Release       Date:  2016-01-12       Impact factor: 9.776

4.  An integrated approach to the ligand binding specificity of Neisseria meningitidis M1 alanine aminopeptidase by fluorogenic substrate profiling, inhibitory studies and molecular modeling.

Authors:  Ewelina Węglarz-Tomczak; Marcin Poręba; Anna Byzia; Łukasz Berlicki; Bogusław Nocek; Rory Mulligan; Andrzej Joachimiak; Marcin Drąg; Artur Mucha
Journal:  Biochimie       Date:  2012-11-03       Impact factor: 4.079

Review 5.  Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicine-Specific Cancer Targeting with Undetectable Toxicity.

Authors:  Daniel W Binzel; Xin Li; Nicolas Burns; Eshan Khan; Wen-Jui Lee; Li-Ching Chen; Satheesh Ellipilli; Wayne Miles; Yuan Soon Ho; Peixuan Guo
Journal:  Chem Rev       Date:  2021-05-26       Impact factor: 72.087

6.  The Rational Design of Therapeutic Peptides for Aminopeptidase N using a Substrate-Based Approach.

Authors:  Shilvi Joshi; Lang Chen; Michael B Winter; Yi-Lun Lin; Yang Yang; Mariya Shapovalova; Paige M Smith; Chang Liu; Fang Li; Aaron M LeBeau
Journal:  Sci Rep       Date:  2017-05-02       Impact factor: 4.379

7.  APN-mediated phosphorylation of BCKDK promotes hepatocellular carcinoma metastasis and proliferation via the ERK signaling pathway.

Authors:  Mengying Zhai; Zixia Yang; Chenrui Zhang; Jinping Li; Jing Jia; Lingyi Zhou; Rong Lu; Zhi Yao; Zheng Fu
Journal:  Cell Death Dis       Date:  2020-05-26       Impact factor: 8.469

8.  Structure-guided, single-point modifications in the phosphinic dipeptide structure yield highly potent and selective inhibitors of neutral aminopeptidases.

Authors:  Stamatia Vassiliou; Ewelina Węglarz-Tomczak; Łukasz Berlicki; Małgorzata Pawełczak; Bogusław Nocek; Rory Mulligan; Andrzej Joachimiak; Artur Mucha
Journal:  J Med Chem       Date:  2014-09-22       Impact factor: 7.446

Review 9.  Molecular Imaging of Aminopeptidase N in Cancer and Angiogenesis.

Authors:  Cynthia L Schreiber; Bradley D Smith
Journal:  Contrast Media Mol Imaging       Date:  2018-06-25       Impact factor: 3.161

Review 10.  Melflufen - a peptidase-potentiated alkylating agent in clinical trials.

Authors:  Malin Wickström; Peter Nygren; Rolf Larsson; Johan Harmenberg; Jakob Lindberg; Per Sjöberg; Markus Jerling; Fredrik Lehmann; Paul Richardson; Kenneth Anderson; Dharminder Chauhan; Joachim Gullbo
Journal:  Oncotarget       Date:  2017-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.